AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.

AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial

Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of

Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of

HUTCHMED shares are trading higher after the company announced high-level results from the SAFFRON Phase III trial.

Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer

First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer